NLS Debt Ratio from 2010 to 2024

NLSPW Stock

USD 0.01 0 18.18%

NLS Pharmaceutics Debt Ratio yearly trend continues to be fairly stable with very little volatility. Debt Ratio will likely drop to 0.97 in 2024. During the period from 2010 to 2024, NLS Pharmaceutics Debt Ratio regression line of quarterly data had mean square error of 153.78 and geometric mean of 2.75. View All Fundamentals

Debt Ratio

First Reported

2010-12-31

Previous Quarter

1.02

Current Value

0.97

Quarterly Volatility

11.96033386

Credit Downgrade

Yuan Drop

Covid

Check NLS Pharmaceutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NLS Pharmaceutics' main balance sheet or income statement drivers, such as Interest Income of 681.3 K, Depreciation And Amortization of 9.8 K or Interest Expense of 137.9 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NLS financial statements analysis is a perfect complement when working with NLS Pharmaceutics Valuation or Volatility modules.

Check out the analysis of NLS Pharmaceutics Correlation against competitors.

Latest NLS Pharmaceutics' Debt Ratio Growth Pattern

Below is the plot of the Debt Ratio of NLS Pharmaceutics AG over the last few years. It is NLS Pharmaceutics' Debt Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NLS Pharmaceutics' overall financial position and show how it may be relating to other accounts over time.

Debt Ratio

10 Years Trend

Very volatile

Compare to Others All Fundamentals

Debt Ratio

Timeline

NLS Debt Ratio Regression Statistics

	Arithmetic Mean	5.76
	Geometric Mean	2.75
	Coefficient Of Variation	207.65
	Mean Deviation	5.73
	Median	3.88
	Standard Deviation	11.96
	Sample Variance	143.05
	Range	47.8207
	R-Value	(0.04)
	Mean Square Error	153.78
	R-Squared	0
	Significance	0.88
	Slope	(0.11)
	Total Sum of Squares	2,003

NLS Debt Ratio History

	2024	0.97
	2023	1.02
	2021	0.88
	2020	1.72
	2019	1.21
	2018	48.71

Other Fundumenentals of NLS Pharmaceutics

Cash Flow To Debt Ratio

NLS Pharmaceutics Debt Ratio component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Capital Surpluse	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Common Stock	Net Receivables	Short Long Term Debt	Capital Stock	Short Term Debt	Current Deferred Revenue
Total Assets		0.89	-0.78	-0.46	0.07	-0.33	0.3	-0.63	0.42	0.99	0.61	0.53	0.13	0.46	0.6	0.38	0.51
Total Stockholder Equity	0.89		-0.82	-0.31	0.06	-0.39	0.4	-0.73	0.42	0.89	0.63	0.32	0.39	0.39	0.47	0.55	0.43
Net Debt	-0.78	-0.82		0.74	-0.58	0.84	-0.82	0.81	0.15	-0.73	-0.1	-0.69	-0.59	-0.77	-0.75	-0.48	-0.8
Retained Earnings	-0.46	-0.31	0.74		-0.79	0.82	-0.8	0.5	0.54	-0.44	0.35	-0.98	-0.19	-0.82	-0.92	-0.17	-0.85
Accounts Payable	0.07	0.06	-0.58	-0.79		-0.88	0.91	-0.22	-0.82	0.0	-0.69	0.65	0.53	0.85	0.67	0.03	0.83
Long Term Debt	-0.33	-0.39	0.84	0.82	-0.88		-0.98	0.66	0.66	-0.26	0.46	-0.69	-0.69	-0.82	-0.67	-0.32	-0.84
Capital Surpluse	0.3	0.4	-0.82	-0.8	0.91	-0.98		-0.56	-0.65	0.24	-0.44	0.67	0.68	0.85	0.71	0.32	0.86
Total Liab	-0.63	-0.73	0.81	0.5	-0.22	0.66	-0.56		0.05	-0.61	-0.18	-0.47	-0.5	-0.36	-0.39	-0.57	-0.43
Net Invested Capital	0.42	0.42	0.15	0.54	-0.82	0.66	-0.65	0.05		0.48	0.96	-0.4	-0.38	-0.49	-0.27	0.12	-0.47
Total Current Assets	0.99	0.89	-0.73	-0.44	0.0	-0.26	0.24	-0.61	0.48		0.66	0.52	0.05	0.4	0.59	0.38	0.45
Net Working Capital	0.61	0.63	-0.1	0.35	-0.69	0.46	-0.44	-0.18	0.96	0.66		-0.23	-0.23	-0.32	-0.08	0.27	-0.29
Common Stock	0.53	0.32	-0.69	-0.98	0.65	-0.69	0.67	-0.47	-0.4	0.52	-0.23		0.03	0.73	0.92	0.09	0.77
Net Receivables	0.13	0.39	-0.59	-0.19	0.53	-0.69	0.68	-0.5	-0.38	0.05	-0.23	0.03		0.39	0.09	0.22	0.38
Short Long Term Debt	0.46	0.39	-0.77	-0.82	0.85	-0.82	0.85	-0.36	-0.49	0.4	-0.32	0.73	0.39		0.78	0.36	1.0
Capital Stock	0.6	0.47	-0.75	-0.92	0.67	-0.67	0.71	-0.39	-0.27	0.59	-0.08	0.92	0.09	0.78		0.14	0.8
Short Term Debt	0.38	0.55	-0.48	-0.17	0.03	-0.32	0.32	-0.57	0.12	0.38	0.27	0.09	0.22	0.36	0.14		0.39
Current Deferred Revenue	0.51	0.43	-0.8	-0.85	0.83	-0.84	0.86	-0.43	-0.47	0.45	-0.29	0.77	0.38	1.0	0.8	0.39

Click cells to compare fundamentals

About NLS Pharmaceutics Financial Statements

NLS Pharmaceutics investors use historical fundamental indicators, such as NLS Pharmaceutics' Debt Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NLS Pharmaceutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Debt Ratio	1.02	0.97
Cash Flow To Debt Ratio	(6.82)	(6.48)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for NLS Stock Analysis

When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

NLS Debt Ratio from 2010 to 2024

Latest NLS Pharmaceutics' Debt Ratio Growth Pattern

NLS Debt Ratio Regression Statistics

NLS Debt Ratio History

Other Fundumenentals of NLS Pharmaceutics

NLS Pharmaceutics Debt Ratio component correlations

About NLS Pharmaceutics Financial Statements

Also Currently Popular

Additional Tools for NLS Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY